Connect with us

Hi, what are you looking for?

Sunday, Apr 20, 2025
Mugglehead Investment Magazine
Alternative investment news based in Vancouver, B.C.
Tilray confirms shutdown of flagship Nanaimo facility
Tilray confirms shutdown of flagship Nanaimo facility
Image via Tilray

Business

Tilray confirms shutdown of flagship Nanaimo facility

The company says it will work with employees interested in transitioning to its Broken Coast facility in North Cowichan

Behemoth Canadian cannabis producer Tilray, Inc. (TSX: TLRY) (Nasdaq: TLRY) is shutting down its flagship facility in Nanaimo, B.C., one of the first licensed commercial cannabis grows in the country.

After NanaimoNewsNow broke the news Wednesday, Tilray confirmed with Mugglehead that it’s shutting down the facility to “optimize operational efficiencies” with the recent business combination with former rival Aphria.

Tilray wouldn’t confirm the number of jobs that are expected to be lost, but reports estimate that number to be between 160–300.

“This closure will roll out in phases and is anticipated to be completed by Spring 2022,” a spokesperson said in an email. “We will work with employees interested in transitioning and seeking opportunities at our nearby facility at Broken Coast on Vancouver Island, B.C.”

Read more: Tilray reduces required shareholder vote count to 1/3 for Aphria merger

Read more: Tilray moves to take large stake in US retailer MedMen

The company says it will concentrate its local B.C. cultivation at the Broken Coast facility, and its international production in Portugal and Germany.

Tilray and Aphria completed a blockbuster merger deal in May. The combined company now operates the following facilities:

  • Broken Coast in North Cowichan, B.C.,
  • Aphria One in Leamington, Ont.,
  • Aphria Diamond in Leamington Ont.,
  • High Park in London, Ont.,
  • Tilray in Cantanhede, Portugal, and
  • Aphria RX GmBH in Neumunster, Germany.

By focusing production at its remaining sites across Canada, Tilray says it will be able to save costs and deliver high-quality products to its patients and consumers, while driving growth and shareholder value.

Tilray reported annual net income of $33.6 million and losses of $336 million in its latest earnings report in July. Company stock peaked during a retail investor frenzy in February at almost US$64 per share, but now trades at US$11.94 on the Nasdaq.

Much of the interest in Tilray’s stock hinges on federal legalization of pot in the U.S.

Read more: Reddit traders send pot stocks to the moon — and back

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

nick@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Cannabis

Rescheduling of the plant in the U.S. is imminent, but we're not quite there yet

Business

Approximately 565 jobs have been cut off this year

Business

The firm could've been immediately on the hook to pay 115% of the principal owed

Business

No explanation has yet been given for the move